1. Biological Factors Linking ApoE ε4 Variant and Severe COVID-19

   • Jameel Inal

   Letter to the Editor 02 October 2020 Article: 70

2. Structural Basis for Vital Function and Malfunction of Serum Amyloid A: an Acute-Phase Protein that Wears Hydrophobicity on Its Sleeve

   • Olga Gursky

   Vascular Biology (J. Hamilton, Section Editor) 24 September 2020 Article: 69

   

3. Therapeutic Apheresis for Management of Lp(a) Hyperlipoproteinemia

   • Sergei N. Pokrovsky
   • Olga I. Afanasieva
   • Marat V. Ezhov

   Nonstatin Drugs (M. Vrablik, Section Editor) 18 September 2020 Article: 68

   

4. The Role of Nutraceuticals in the Optimization of Lipid-Lowering Therapy in High-Risk Patients with Dyslipidaemia

   • Peter E. Penson
   • Maciej Banach

   Nonstatin Drugs (M. Vrablik, Section Editor) Open access 18 September 2020 Article: 67

5. Targeting Inflammation to Reduce Residual Cardiovascular Risk

   • Oluremi N. Ajala
   • Brendan M. Everett

   Nonstatin Drugs (M. Vrablik, Section Editor) 03 September 2020 Article: 66

   

6. Gender Differences in Residual Risk Factors for Major Adverse Cardiovascular Events Following ACS and How to Bridge the Gap

   • Olivia Manfrini
   • Edina Cenko
   • Raffaele Bugiardini

   Women and Ischemic Heart Disease (P. Kohli, Section Editor) 03 September 2020 Article: 65

   

7. The Knowns and Unknowns of Contemporary Statin Therapy for Familial Hypercholesterolemia

   • Jing Pang
   • Dick C. Chan
   • Gerald F. Watts

   Statin Drugs (R. Ceska, Section Editor) 01 September 2020 Article: 64

8. Familial Chylomicronemia Syndrome (FCS): Recent Data on Diagnosis and Treatment

   • Antonio Gallo
   • Sophie Béliard
   • Eric Bruckert

   Statin Drugs (R Ceska, Section Editor) 27 August 2020 Article: 63